At the Annual General Assembly, Dr. Reijo Salonen, MD, PhD and Dr. Anders Fugelli, PhD were elected to the Board of Directors of Pharmasum Therapeutics. At the same time, the Company closed a significant funding round, allowing it to accelerate the designation of its Development Candidate for cognitive dysfunctions and dementia.